Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 20/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 19/20 | 0.62 |
| ▸ | FGFR2 | P21802 | 19/20 | 0.62 |
| ▸ | FGFR4 | P22455 | 19/20 | 0.62 |
| ▸ | KDR | P35968 | 16/20 | 0.62 |
| ▸ | FLT3 | P36888 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20309680 | 0.91 | FGFR3 (0.58) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14901146 | 0.90 | FGFR1 (0.75) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14901209 | 0.86 | FGFR1 (0.64) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL20309743 | 0.86 | FGFR3 (0.58) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL16125133 | 0.86 | FGFR1 (0.65) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL20309625 | 0.86 | FGFR4 (0.52) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL16125208 | 0.85 | FGFR3 (0.75) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14901164 | 0.85 | FGFR3 (0.74) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL14901201 | 0.85 | FGFR1 (0.58) | FGFR3FGFR1FGFR2FGFR4KDR | |
| SCHEMBL18021081 | 0.84 | FGFR3 (0.73) | FGFR3FGFR1FGFR2FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-9309242-B2 | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309242-B2 | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004733-B2 | — | SDHB, SDHA, NDUFS5 | FGFR3 2208/4885FGFR1 1458/4885FGFR2 1755/4885 |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR2, FGFR4 | FGFR3 4/4885FGFR1 1/4885FGFR2 2/4885 |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | FGFR3 3/4885FGFR1 1/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.